10 assets in Ovarian Adenocarcinoma

Therapeutic assets addressing Ovarian Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Ovarian Adenocarcinoma	TCR2 Therapeutics	P1/2	CCC (54)
Ipilimumab Ovarian Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Niraparib Ovarian Adenocarcinoma	CanariaBio Inc.	P2	CCC (53)
Nivolumab Ovarian Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fludarabine Ovarian Adenocarcinoma	TCR2 Therapeutics	P1/2	CCC (48)
Pasifolate Exatecan Ovarian Adenocarcinoma	Elucida Oncology	P1/2	CCC (48)
tc-510 Ovarian Adenocarcinoma	TCR2 Therapeutics	P1/2	CCC (48)
Oregovamab Ovarian Adenocarcinoma	CanariaBio Inc.	P2	CC (47)
Avb-001 Ovarian Adenocarcinoma	Avenge Bio, Inc	P1/2	NR ()
Tolinapant Ovarian Adenocarcinoma	National Cancer Institute (NCI)	P1/2	NR ()